{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:58:36Z","timestamp":1773154716550,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Reports in Hematology"],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:p>Plasmablastic lymphomas and plasmablastic myelomas are malignancies with overlapping clinical and pathological features which pose a diagnostic dilemma and are known to be aggressive with a poor outcome. CD38 is a common immunophenotypic maker for both these malignancies and provides a rationale for using daratumumab-based regimes. We describe a 57-year-old male with a history of end-stage renal disease who underwent a deceased-donor renal transplant maintained on chronic immunosuppression who presented with ascites and was found to have abdominal adenopathy and a lytic lesion in the humerus and diagnosed with a post-transplant lymphoproliferative disorder with features intermediate between plasmablastic lymphoma and plasmablastic myeloma. The patient was subsequently treated with a daratumumab-based regime with an excellent response. This case highlights a rare scenario that poses a diagnostic and therapeutic challenge. As there is no standard of care for the treatment of both these malignancies, this case report also describes the use of daratumumab with a good long-term outcome, especially when the pathological distinction between the two entities is difficult.<\/jats:p>","DOI":"10.1155\/2021\/4354941","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:50:10Z","timestamp":1632793810000},"page":"1-5","source":"Crossref","is-referenced-by-count":7,"title":["Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7547-2315","authenticated-orcid":true,"given":"Poornima","family":"Ramadas","sequence":"first","affiliation":[{"name":"SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA"},{"name":"LSU Health Sciences Center, 1501 Kings Hwy, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Williams","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Duggan","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199012203232510"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v91.7.2501.2501_2501_2507"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.15406\/htij.2018.06.00146"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.516040"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2005.07.009"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0b013e3181f3e29f"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0304"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1159\/000504608"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25955"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/apm.12411","article-title":"Clinicopathological features of plasmablastic multiple myeloma: a population\u2010based cohort","volume":"123","author":"H. E. M\u00f8ller","year":"2015","journal-title":"Apmis"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.5.1551"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800355"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204294"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-234436"},{"key":"16","article-title":"A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma","volume":"105","author":"C. R. Tan","year":"2021","journal-title":"AIDS Malignancy Consortium"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3673"}],"container-title":["Case Reports in Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crihem\/2021\/4354941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crihem\/2021\/4354941.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crihem\/2021\/4354941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:50:11Z","timestamp":1632793811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crihem\/2021\/4354941\/"}},"subtitle":[],"editor":[{"given":"Salah","family":"Aref","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":17,"alternative-id":["4354941","4354941"],"URL":"https:\/\/doi.org\/10.1155\/2021\/4354941","relation":{},"ISSN":["2090-6579","2090-6560"],"issn-type":[{"value":"2090-6579","type":"electronic"},{"value":"2090-6560","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,27]]}}}